OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer
Khalil Saleh, Rita Khoury, Nadine Khalife, et al.
Cancer Drug Resistance (2024)
Open Access | Times Cited: 7
Khalil Saleh, Rita Khoury, Nadine Khalife, et al.
Cancer Drug Resistance (2024)
Open Access | Times Cited: 7
Showing 7 citing articles:
Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: A systematic review and updated meta-analysis
Isabella Michelon, Caio Castro, Thiago Madeira, et al.
Cancer Treatment Reviews (2025) Vol. 133, pp. 102882-102882
Closed Access
Isabella Michelon, Caio Castro, Thiago Madeira, et al.
Cancer Treatment Reviews (2025) Vol. 133, pp. 102882-102882
Closed Access
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma
Laura Scalambra, Francesca Ruzzi, Olga Maria Pittino, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Laura Scalambra, Francesca Ruzzi, Olga Maria Pittino, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing
Éric Larose, Xinying Hua, Silin Yu, et al.
Cancer Drug Resistance (2025)
Open Access
Éric Larose, Xinying Hua, Silin Yu, et al.
Cancer Drug Resistance (2025)
Open Access
Efficacy and safety of pyrotinib in the treatment of HER2-positive liver metastatic advanced breast cancer
Yongxia Li, Yong Li, Taolang Li, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Yongxia Li, Yong Li, Taolang Li, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Current progress and remaining challenges of peptide–drug conjugates (PDCs): next generation of antibody-drug conjugates (ADCs)?
Dongyuan Wang, Feng Yin, Zigang Li, et al.
Journal of Nanobiotechnology (2025) Vol. 23, Iss. 1
Open Access
Dongyuan Wang, Feng Yin, Zigang Li, et al.
Journal of Nanobiotechnology (2025) Vol. 23, Iss. 1
Open Access
Predictive Factors of Antibody–Drug Conjugate Treatment in Metastatic Breast Cancer: A Narrative Review
Gennaro Gadaleta‐Caldarola, Laura Lanotte, Anna Santoro, et al.
Cancers (2024) Vol. 16, Iss. 23, pp. 4082-4082
Open Access
Gennaro Gadaleta‐Caldarola, Laura Lanotte, Anna Santoro, et al.
Cancers (2024) Vol. 16, Iss. 23, pp. 4082-4082
Open Access
Unlocking Natural Potential: Antibody‐Drug Conjugates With Naturally Derived Payloads for Cancer Therapy
Xue Jiang, Wan Najbah Nik Nabil, Yufei Ze, et al.
Phytotherapy Research (2024)
Closed Access
Xue Jiang, Wan Najbah Nik Nabil, Yufei Ze, et al.
Phytotherapy Research (2024)
Closed Access
